Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,593–1,600 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Eli Lilly and Company Orforglipron - (ACHIEVE-4) Type 2 Diabetes Phase 3 Ongoing Oral Endocrinology
Eli Lilly and Company RETEVMO (Selpercatinib) - (LIBRETTO-531) Medullary thyroid cancer (MTC) Phase 3 Data Released Oral Oncology
Eli Lilly and Company 177Lu-PNT2002 - (SPLASH) Metastatic Castration-Resistant Prostate Cancer Phase 3 Data Released Intravenous Oncology
Eli Lilly and Company CYRAMZA (ramucirumab) - RAINFALL First-line gastric cancer Phase 3 Intravenous Oncology
Eli Lilly and Company MORF-057-202 - (EMERALD-2) Ulcerative Colitis (UC) Phase 2b Ongoing Oral Gastroenterology
Eli Lilly and Company Baricitinib - (BRAVE-AA-PEDS) Severe alopecia areata (AA) Phase 3 Data Released Oral Immunology
Eli Lilly and Company Rezpegaldesleukin (LY3471851) - (REZOLVE-AD) Atopic Dermatitis Phase 2b Data Released Subcutaneous Immunology
Eli Lilly and Company Solanezumab Inherited Alzheimer's disease Phase 2/3 Intravenous Genetic Disorder